SCHEMBL1996072

SCHEMBL1996072

c1ccc(-c2ccccc2Nc2nc3ccccc3[nH]2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.63
RAB9A P51151 8/20 0.58
NPC1 O15118 7/20 0.58
MAPT P10636 3/20 0.58
TP53 P04637 2/20 0.58
LMNA P02545 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
SMN1; SMN2 Q16637 7/20 0.55
ALDH1A1 P00352 3/20 0.55
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
ALOX15 P16050 2/20 0.51
HPGD P15428 1/20 0.51
PLK4 O00444 1/20 0.49
AURKA O14965 1/20 0.49
ROCK2 O75116 1/20 0.49
MAP4K4 O95819 1/20 0.49
CHEK2 O96017 1/20 0.49
PIM1 P11309 1/20 0.49
AXL P30530 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2928349 0.80 HDAC6 (0.55) LMNANPSR1SMN1; SMN2ALDH1A1CHEK2
SCHEMBL28050241 0.79 RAB9A (0.68) GAARAB9ANPC1MAPTTP53
SCHEMBL5695253 0.78 GAA (0.67) GAARAB9ANPC1MAPTTP53
SCHEMBL31451868 0.78 GAA (0.67) GAARAB9ANPC1MAPTTP53
SCHEMBL5695258 0.78 GAA (0.67) GAARAB9ANPC1MAPTTP53
SCHEMBL5695259 0.78 GAA (0.67) GAARAB9ANPC1MAPTTP53
SCHEMBL3612086 0.78 GAA (0.67) GAARAB9ANPC1MAPTTP53
SCHEMBL9081342 0.78 GAA (1.00) GAARAB9ANPC1MAPTTP53
SCHEMBL28728369 0.77 RAB9A (0.66) GAARAB9ANPC1MAPTTP53
SCHEMBL239690 0.76 MEN1 (0.75) GAARAB9ANPC1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels NEUROSEARCH A/S (DK) 2009-03-19 US claimed
US-7960561-B2 2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels NEUROSEARCH A/S (DK) 2011-06-14 US disclosed
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels NEUROSEARCH A/S (DK) 2009-03-19 US disclosed
EP-1896427-A2 NOVEL 2-(PHENYLAMINO)BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NeuroSearch A/S (DK) 2008-03-12 EP disclosed
WO-2006136580-A2 2-(PHENYLAMINO)BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels KCNN2, KCNN1, KCNN3 GAA 2861/4885RAB9A 2556/4885NPC1 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.